The pan-hematopoietic marker CD45 was applied to detect TN-hybrid cells in the ascites fluid of ovarian cancer patients and in the circulation of melanoma and pancreatic cancer patients [20,29,41,42]. This evidence concerns the gene PTPRC and familial pancreatic carcinoma.